Fully Human Anti-Candida Antibodies for Diagnostics and Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostics and treatments for fungal infections, particularly those caused by Candida species, are limited by narrow spectra of activity and lack of effective vaccines, leading to high mortality rates and poor prognosis due to late diagnosis and inaccurate therapy.
Innovation Solution
Development of fully human recombinant IgG1 monoclonal antibodies (mAbs) targeting Candida albicans antigens, specifically the Hyr1 protein, derived from single B cells of donors with mucosal infections, which exhibit diverse binding profiles and efficacy in murine models, enabling diagnostic and therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If murine monoclonal antibodies are used to target fungal antigens, then protective effects are achieved through neutralizing antibodies, but immunogenicity issues arise and therapeutic efficacy is limited in human patients
Solution Approach 1:
The patent applies parameter changes by transitioning from murine to fully human antibody sequences, fundamentally changing the biological origin parameter of the antibody to eliminate immunogenicity while maintaining therapeutic efficacy. This is achieved by isolating and cloning human B cells that naturally produce anti-fungal antibodies, then expressing these human antibody sequences in human cell lines.
Solution Approach 2:
The patent uses copying by replicating naturally occurring human antibody sequences from donor B cells. Instead of generating artificial murine antibodies, the invention copies the exact amino acid sequences of human antibodies that have evolved to recognize fungal antigens, ensuring compatibility with the human immune system while maintaining protective function.
2Adaptability or versatility
If broad-spectrum antifungal treatments are developed, then coverage of multiple Candida species is improved, but specificity and accuracy of therapy are reduced
Solution Approach 1:
The patent applies universality by developing antibody panels that can recognize multiple Candida species through shared epitopes. The isolated human antibodies demonstrate cross-reactivity across different Candida species while maintaining the ability to distinguish between them, enabling both broad coverage and specific identification through the same reagent panel.
Solution Approach 2:
The patent applies local quality by creating antibodies with different specificities within the same therapeutic platform. Individual antibodies in the panel are optimized for specific species or epitopes, allowing the system to provide both broad-spectrum coverage and species-specific diagnosis by selecting appropriate antibodies from the panel based on clinical needs.
3Reliability
If experimental vaccines based on fungal cell wall targets are developed, then protective effects are achieved through eliciting neutralizing antibodies, but clinical effectiveness and mortality reduction are insufficient
Solution Approach 1:
The patent applies self-service by isolating antibodies from human donors who have naturally developed protective immunity against fungal infections. Instead of attempting to engineer vaccines that mimic natural immunity, the invention directly harvests the antibodies that the human immune system has already proven effective, ensuring clinical relevance and efficacy.
Solution Approach 2:
The patent applies preliminary action by identifying and isolating protective antibodies from donors before clinical application. The antibodies are pre-selected and characterized for their ability to neutralize fungal pathogens, then manufactured and stored for immediate therapeutic use, eliminating the need for slow vaccine development and approval processes.
Data Source
AI summary
This invention relates to recombinant human antibody molecules. The antibodies bind fungal antigens, for example from Candida spp. Human antibody encoding genes targeting clinically relevant Candida epitopes have been isolated from single B cells from carefully selected donors and screened with specified types of protein or cell wall extract. The panel of purified, fully human recombinant IgG1 mAbs generated displayed a diverse range of specific binding profiles and demonstrated efficacy in a disease model. The fully human mAbs and derivatives thereof have utility in the generation of diagnostics, therapeutics and vaccines.